These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 12143912

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ.
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL.
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [Abstract] [Full Text] [Related]

  • 4. Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study.
    Labelle A, Bourget D, Boulay LJ, Ellis J, Tessier P.
    J Clin Psychopharmacol; 2002 Dec; 22(6):545-53. PubMed ID: 12454553
    [Abstract] [Full Text] [Related]

  • 5. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
    Lindenmayer JP, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, Czobor P, Parker B, Iskander A.
    J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G, Ziprasidonra Váltást Vizsgáló Munkacsoport.
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.
    Dossenbach MRK, Beuzen JN, Avnon M, Belmaker RH, Elizur A, Mark M, Munitz H, Schneidman M, Shoshani D, Kratky P, Grundy SL, Tollefson GD.
    Clin Ther; 2000 Sep; 22(9):1021-34. PubMed ID: 11048902
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial.
    Chiu NY, Yang YK, Chen PS, Chang CC, Lee IH, Lee JR.
    Psychiatry Clin Neurosci; 2003 Oct; 57(5):478-84. PubMed ID: 12950701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.